Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Zelensky warns of imminent massive Russian attack on Ukraine - 2EU states agree first step for Ukraine reparations fund
- 3Holiday destinations for Creature Sweethearts
- 4Embracing Practical Living and Ecological Protection
- 5'Not the moon that I'm used to seeing': Artemis II astronauts describe seeing the far side
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- Polish law aimed at lowering petrol prices takes effect
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- Worldwide Objections Ideal For A Golf Outing
- Toyota’s Next Big Sports Car Might Apparently Be a Turbocharged All-Paw Beast
- Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- Israeli lawmakers pass bill reviving death penalty for terrorists
- Solid Living Tips: Experiences from a Wellness Fan
